Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tenofovir Disoproxil · Viread, TDF

Small molecule · Inhibitor of HIV-1 reverse transcriptase and HBV reverse transcriptase · developed by Gilead Sciences

Approved FDA
GILD Developer
3 Registered trials

What is Tenofovir Disoproxil?

Tenofovir disoproxil is a prodrug of tenofovir, a nucleotide analog that inhibits the reverse transcriptase of HIV-1 and hepatitis B virus. It is used in combination with other antiretroviral agents for HIV-1 infection and for chronic hepatitis B, and is also studied in HIV pre-exposure prophylaxis and hepatitis D.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Viread, TDF, PTM F/TDF
Drug type
Small molecule
Targets
HIV-1 reverse transcriptase, HBV reverse transcriptase
Mechanism
Inhibitor of HIV-1 reverse transcriptase and HBV reverse transcriptase
Therapy area
Infectious disease
Developer
Gilead Sciences, Inc. (GILD)
Also in trials of
ALGS, ARWR
FDA status
Approved as Viread, NDA021356 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04925752 Phase 3 Pre-Exposure Prophylaxis of HIV Infection Active not recruiting GILD
NCT06963710 Phase 2 Chronic Hepatitis B Infection Active not recruiting ALGS
NCT02577029 Phase 2 Hepatitis B Terminated ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B InfectionPre-Exposure Prophylaxis of HIV InfectionHepatitis BHepatitis D

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Tenofovir Disoproxil

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.